The Latest Breaking News from Pfizer

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Wall Street soared to fresh record highs at the end of the week, brushing aside the 21st U.S. government shutdown in history and a missing jobs report, as investors doubled down on bets for interest rate cuts and cheered strong gains in pharmaceutical and AI-driven tech stocks.

Health care stocks are on track for their best week in years, yet even after the rally, several pharma giants remain absurdly cheap by market standards.